Intriguingly, recent studies highlight GPD1L’s tumor-suppressive potential across diverse malignancies, including HER2-negative breast cancer (20), esophageal squamous cell carcinoma (21), and gastric carcinoma (22), though its role in CRC remained unexplored prior to this investigation. This evidence concerns the gene ERBB2 and gastric carcinoma.